
The development of cancer vaccines has been one of the several false zzso in which initial promising Phase I and Phase II clinical data have not been followed up with conclusive Phase III zzso In this review, we describe some of the successes and failures, and review the most likely reasons for Phase III failure, such as protocol changes, which are common between Phase II and III, and poorly defined patient zzso Nevertheless, significant survival results have been reported with zzso vaccines for zzso zzso and, more recently, prostate zzso In addition, it is becoming evident that zzso is potentially synergistic with other treatment zzso such as chemotherapy, which can reduce zzso activity that zzso the immune response to cancer zzso This potential for zzso should allow cancer vaccines to become part of the standard treatment regimen for many common zzso 

